Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma
Katrin J. Ciecielski(TUM Klinikum), Sara Mainardi(The Netherlands Cancer Institute), Hana Algül(TUM Klinikum), Natalie Proost(The Netherlands Cancer Institute), Susanne Kossatz(TUM Klinikum), René Bernards(The Netherlands Cancer Institute), Astrid Bosma(The Netherlands Cancer Institute), Bruno Sáinz(Instituto de Salud Carlos III), Larissa Heinemann(TUM Klinikum), Kalliope N. Diakopoulos(Beth Israel Deaconess Medical Center), Laura Cañas(Hospital Universitari Germans Trias i Pujol), Nan Wu(TUM Klinikum), Antonio Mulero‐Sánchez(Oncode Institute), Dietrich Alexander Ruess(University Medical Center Freiburg), Bram Thijssen(The Netherlands Cancer Institute), Marina Lesina(TUM Klinikum), Yuhui Fan(Tongji University), Wolfgang Weber(Nuklearmedizinische Klinik des Klinikums rechts der Isar), Derya Kabacaoğlu(TUM Klinikum), Ezgi Kaya-Aksoy(TUM Klinikum), Alexandra Berninger(TUM Klinikum), Fränze Schmidt(TUM Klinikum), Marieke van de Ven(The Netherlands Cancer Institute)
Cited by 2
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
|Autophagy|2016|6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k